MannkindLogoStackedPreferd.jpg
MannKind Corporation Reports 2022 Second Quarter Financial Results
August 09, 2022 16:00 ET | MannKind
Conference Call to Begin Today at 5:00 p.m. (ET) Tyvaso DPI™ approved by the FDA in May representing the second FDA-approved product using the Technosphere® inhalation platform V-Go® acquired May...
MannkindLogoStackedPreferd.jpg
MannKind Corporation to Hold 2022 Second Quarter Financial Results Conference Call on August 9, 2022
August 02, 2022 06:00 ET | MannKind
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2022 second quarter and year to date financial results and its...
MannkindLogoStackedPreferd.jpg
MannKind Corporation to Participate in the BTIG Biotechnology Conference
August 01, 2022 06:00 ET | MannKind
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative...
MannkindLogoStackedPreferd.jpg
Mannkind to Host Product Theater and Booth at the American Diabetes Association’s 82nd Scientific Sessions in New Orleans, June 3-7
June 03, 2022 10:00 ET | MannKind
WESTLAKE VILLAGE, Calif., June 03, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative therapeutic products for...
MannKind’s Technosphere® Inhalation Platform Utilized in FDA-Approved Tyvaso DPI™
May 24, 2022 06:00 ET | MannKind
Tyvaso DPI represents the second FDA-approved product utilizing MannKind’s Technosphere® inhalation technologyFirst approval of a dry powder inhaled treatment for PAH and PH-ILDManufacturing of Tyvaso...
MannkindLogoStackedPreferd.jpg
MannKind Corporation to Ring the Nasdaq Stock Market Opening Bell
May 19, 2022 06:00 ET | MannKind
WESTLAKE VILLAGE, Calif. and DANBURY, Conn., May 19, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic...
MannKind Corporation Announces Agreement to Acquire V-Go® Insulin Delivery Device From Zealand Pharma
May 17, 2022 06:06 ET | MannKind
The once-daily insulin delivery device strengthens MannKind’s commitment to offering innovative mealtime diabetes solutions DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 17, 2022 (GLOBE...
MannkindLogoStackedPreferd.jpg
MannKind Corporation Participating at Upcoming Conferences
May 09, 2022 06:00 ET | MannKind
WESTLAKE VILLAGE, Calif. and DANBURY, Conn., May 09, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic...
MannkindLogoStackedPreferd.jpg
MannKind Corporation Reports 2022 First Quarter Financial Results
May 05, 2022 16:00 ET | MannKind
1Q 2022 Afrezza Net Revenue of $9.8 million; +21% vs. 1Q 20211Q 2022 Afrezza Gross Margin 77%; Gross Profit +99% vs 1Q 2021$233.0 million of Cash, Cash Equivalents, and Investments at March 31,...
MannkindLogoStackedPreferd.jpg
MannKind Corporation to Hold 2022 First Quarter Financial Results Conference Call on May 5, 2022
April 28, 2022 06:00 ET | MannKind
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2022 first quarter financial results and its management will host...